ESR1 and breast carcinoma: In NSCLC, reduced miRNA-145 boosts EGFR, promoting cell growth and erlotinib resistance.710 Conversely, miR-145 inhibits platelet-derived growth factor receptor, decreasing proliferation and increasing erlotinib and gefitinib sensitivity.711 In breast cancer, miR-335-5p and miR-335-3p work in tandem to suppress estrogen receptor α, thereby heightening tamoxifen resistance.712 miRNAs influence therapy sensitivity by regulating processes like apoptosis, cell cycle, and EMT.